AGL 8.30 Decreased By ▼ -0.03 (-0.36%)
ANL 10.95 Increased By ▲ 0.25 (2.34%)
AVN 79.70 Increased By ▲ 1.51 (1.93%)
BOP 5.75 Increased By ▲ 0.18 (3.23%)
CNERGY 5.64 Increased By ▲ 0.26 (4.83%)
EFERT 79.36 Increased By ▲ 0.71 (0.9%)
EPCL 67.48 Decreased By ▼ -0.31 (-0.46%)
FCCL 14.89 Increased By ▲ 0.39 (2.69%)
FFL 6.70 Increased By ▲ 0.10 (1.52%)
FLYNG 7.16 Increased By ▲ 0.13 (1.85%)
GGGL 11.60 Increased By ▲ 0.26 (2.29%)
GGL 17.51 Increased By ▲ 0.27 (1.57%)
GTECH 8.35 Increased By ▲ 0.05 (0.6%)
HUMNL 7.17 Increased By ▲ 0.11 (1.56%)
KEL 3.14 Increased By ▲ 0.06 (1.95%)
LOTCHEM 35.20 Increased By ▲ 2.33 (7.09%)
MLCF 28.35 Increased By ▲ 0.05 (0.18%)
OGDC 87.70 Increased By ▲ 3.15 (3.73%)
PAEL 16.63 Increased By ▲ 0.18 (1.09%)
PIBTL 6.05 Increased By ▲ 0.20 (3.42%)
PRL 19.46 Increased By ▲ 1.34 (7.4%)
SILK 1.14 No Change ▼ 0.00 (0%)
TELE 11.41 Increased By ▲ 0.31 (2.79%)
TPL 9.20 Increased By ▲ 0.20 (2.22%)
TPLP 20.25 Increased By ▲ 0.37 (1.86%)
TREET 27.10 Increased By ▲ 0.48 (1.8%)
TRG 96.20 Increased By ▲ 1.70 (1.8%)
UNITY 20.85 Increased By ▲ 0.48 (2.36%)
WAVES 13.90 Increased By ▲ 0.27 (1.98%)
WTL 1.34 Increased By ▲ 0.03 (2.29%)
BR100 4,275 Increased By 67 (1.59%)
BR30 15,794 Increased By 348.3 (2.26%)
KSE100 42,872 Increased By 628.4 (1.49%)
KSE30 16,219 Increased By 247.6 (1.55%)

NEW YORK: Moderna cut its 2021 forecast for Covid-19 vaccine deliveries on Thursday, pushing back some doses to next year and sending shares sharply lower.

The biotech company, which has soared to prominence this year on the success of its coronavirus vaccine, cited longer delivery times for international shipments.

Other factors concern "temporary" impacts associated with the ramp up of production, said Moderna, adding that some shipments would lapse until early 2022.

Moderna now expects 2021 vaccine deliveries of between 700 and 800 million doses, down from the prior range of 800 million to one billion.

Moderna reported profits of $3.3 billion in the quarter from July to September, compared with a loss of $233 million in the year-ago period.

Moderna says its Covid-19 shot 93% effective six months after second dose

Revenues came in just shy of $5 billion, exponentially above the $157 million in the 2020 stretch, but below the $6.2 billion expected by analysts.

Moderna said it has agreements for $17 billion worth of sales in 2022 for vaccines, with options for another $3 billion.

The company said commercial booster sales could also hit $2 billion.

U.S. FDA leaning toward approving Moderna half-dose booster

Moderna's announcement comes after Pfizer earlier this week boosted its 2021 forecast as it ramps up production. The pharma giant now expects to deliver 2.3 billion doses in 2021 of the Covid-19 vaccine jointly produced with Germany's BioNTech, 200 million more than the company forecast in July.

Shares of Moderna fell 16.6 percent to $288.50 in mid-morning trading.

Comments

Comments are closed.